Why Buyers Get Stuck: Diagnosing the Gaps After Your Health Product Gains Visibility
When the right potential customers are finding your health product but not moving much further, visibility may no longer be the problem. The friction may sit in what they still need to understand, trust, compare, or justify—and diagnosing that gap can show you what communication needs to do next.
The visibility work appears to be paying off.
A partnership announcement brings relevant traffic.
A conference presentation generates enquiries from the organizations you wanted to reach.
A targeted campaign attracts the right professional audiences.
Demo requests increase.
The product is getting seen by the right people. But that attention is not translating into meaningful progress.
If visibility is no longer the main problem, what is?
Conversations stay preliminary. Interest does not develop into serious evaluation. The organizations engaging with the product still seem to need more before they can move forward.
Relevant visibility changes what weak commercial movement can mean
Before a company has sufficient visibility, weak demand is difficult to interpret.
The positioning may be unclear. The offer may be difficult to evaluate. Buyers may not understand the evidence or see how implementation would work. But there is also a simpler possibility: too few relevant people have encountered the product.
A visibility initiative can help separate these possibilities—but only if it reaches the intended market.
A widely shared founder post may generate attention among peers without attracting prospective customers. Media coverage may send thousands of visitors to a digital-health company’s website while reaching few people involved in an institutional purchase. Even a rise in demo requests reveals little if most enquiries come from organizations outside the product’s intended market.
Before interpreting what happened after the campaign, establish whether the visibility was commercially relevant.
Did it bring in organizations with a plausible need for the product? Were the people engaging connected to evaluation, adoption, or purchase? Did they encounter the company in a context that could reasonably lead to commercial consideration?
Here, “qualified buyers” does not mean that every person has completed a formal Sales qualification process or is ready to purchase. It means the increased attention includes people and organizations that reasonably match the intended market and use case.
If it does not, limited commercial movement may still be primarily a targeting or distribution problem. If it does, insufficient awareness becomes a less complete explanation. The diagnostic question changes from “How do we attract more attention?” to “Now that relevant buyers are arriving, what are they still unable to evaluate or decide?”
This does not make the answer obvious. Budget constraints, timing, weak follow-up, competing priorities, or a short observation period may all affect movement. But the company now has qualified activity at a part of the buyer journey that was previously difficult to examine.
What happens there can provide more useful information than the broad conclusion that conversion disappointed.
A buyer can be interested without being able to evaluate the product
Visibility can create recognition:
This product appears relevant to a problem we have.
Evaluation requires more:
We can determine whether this product is credible, appropriate, and workable in our organization.
In B2B health, the distance between these two states can be substantial.
Depending on the product and setting, buyers may need to assess clinical or technical performance, economic impact, applicability to a particular population, data protection, technical security, interoperability, usability, accessibility, and operational requirements.
This complexity is visible in formal digital-health evaluation frameworks. NICE’s evidence standards framework addresses evidence of effectiveness and economic impact. NHS England’s Digital Technology Assessment Criteria cover clinical safety, data protection, technical security, interoperability, usability, and accessibility.
Not every buyer uses these particular frameworks, and not every health product is subject to the same assessment. They illustrate a wider commercial constraint: understanding the promise is not the same as having enough information to make a decision about it.
Consider a digital mental-health platform selling to employers and healthcare providers.
An HR leader may recognize the relevance of the problem immediately.
Clinical leadership may need to determine whether the evidence supports the proposed use.
IT may need to understand integration, security, and data flows.
An operational owner may want to know what adoption will require from staff.
Procurement may need a credible financial case.
The organization is interested. But interest alone does not resolve any of these decisions.
This is why high engagement can coexist with limited progression. Downloading a report, attending a webinar, or requesting introductory information may show that the subject matters to someone. It does not establish that the buyer can evaluate the product, mobilize the necessary stakeholders, or justify the next step.
The visibility initiative may have improved recognition while leaving evaluability largely unchanged.
Find the first buyer decision that did not improve
A final conversion rate compresses several decisions into one number. To understand what happened, look for the first meaningful decision qualified buyers still struggle to complete.
Can buyers recognize that the offer is meant for them?
A buyer may understand the general product category but remain unsure whether the offer was designed for an organization like theirs.
The company may describe several audiences, use cases, or problems without establishing which combination represents its strongest fit. The resulting message attracts relevant interest, but buyers still have to work out whether their own setting falls within the offer.
This points toward a possible positioning or targeting problem. More reach may bring in more people who experience the same uncertainty.
Can they identify what materially changes through adoption?
Some companies explain their capabilities clearly while leaving the commercial consequence implicit.
A buyer can understand what the platform measures, automates, monitors, or delivers and still be unable to determine what adopting it would improve.
Which current problem would become easier to manage? What work would decrease? What risk would be reduced? What new capability would become possible? Why does the difference justify organizational attention now?
The buyer is not missing another feature explanation. The unresolved decision sits between product capability and practical value.
Can they judge whether the evidence is sufficient and relevant?
A company may present studies, expert credentials, technical documentation, and multiple citations without making the evidence easier to use.
The buyer may still need to determine:
- which claim each source supports;
- whether the studied population resembles the intended users;
- whether the measured outcome matters in the proposed setting;
- how mature the evidence is;
- what remains uncertain.
The problem is not necessarily an absence of evidence. It may be an absence of decision relevance.
If the buyer has to reconstruct the relationship between the evidence and the proposed use, the company has transferred the work of interpretation to the person it is asking to proceed.
Can they see what adoption would require?
A buyer may accept your health product’s value and evidential basis while remaining uncertain about implementation.
Who would own it internally? Which workflows would change? What training would be required? What systems must connect? How much staff time would adoption consume? What happens after the initial rollout?
These are not secondary questions that appear after the “real” buying decision. They are part of the decision.
A 2026 systematic review of 204 empirical studies across 23 high-income countries found that digital-health implementation in primary care depended on the interaction of technological, organizational, and policy conditions. The review cannot explain why an individual prospect stalled, but it supports the narrower conclusion that implementation depends on more than perceived product benefit.
When interested buyers repeatedly return to workflow, staffing, integration, or internal ownership, they may not require more persuasion. They may be trying to determine whether adoption is workable.
Can they complete the next organizational step?
Sometimes the buyer understands the product, recognizes its value, and considers the evidence credible—but still cannot progress the decision.
The next step offered by the company may be too large for the buyer’s current level of certainty. A standard “book a demo” invitation may start a conversation without helping the buyer prepare for what follows. Sales materials may explain the product well but give the internal champion little support for conversations with clinical, technical, financial, or executive stakeholders.
At this stage, the issue is neither initial relevance nor product comprehension.
If a buyer lacks a usable route from individual interest to organizational consideration, the company has created demand but has not adequately supported progression.
Is the answer inaccessible, unstable, or missing?
Locating the first incomplete buyer decision is not enough. The company must also establish why the decision remains difficult.
Suppose prospects repeatedly ask:
How would this fit into our existing workflow?
There are at least three materially different possibilities.
1. The answer exists but is inaccessible
Your health company has a clear implementation model. Sales can explain it consistently. Existing clients recognize it. But buyers cannot find or understand the information at the point when they need it.
This is primarily a communication or content-architecture problem. The answer may need to appear earlier, in a more useful form, or in materials that buyers can circulate internally.
2. The answer exists, but only as unstable internal knowledge
The founder explains implementation one way. Sales describes it another way. Product assumes a level of customization that Operations cannot reliably deliver.
The health company is not missing every part of the answer, but it does not yet have one stable enough to communicate consistently.
Publishing another implementation page at this stage risks selecting one version of an unresolved internal decision and presenting it as settled. The immediate work is alignment: establishing what the company can actually promise, what varies, and what must be decided case by case.
3. The answer does not yet exist
Implementation may still be designed during each sale. Resource requirements may be unknown. Integration assumptions may be untested. The company may not know which internal role must own adoption.
This is not a content problem. Communication can clarify known requirements, reduce unnecessary ambiguity, and help buyers navigate complexity. It cannot make an unresolved operating model decision-ready.
The distinction matters because the same visible symptom—buyers asking for more information—can lead to three different interventions.
The question tells you what the buyer cannot determine. It does not tell you whether the answer needs to be communicated, stabilized, or developed.
Match the intervention to the unresolved decision
Once relevant buyers are entering the journey, the next investment should correspond to the first decision they cannot complete.
| What appears to be stalling? | What to investigate next |
|---|---|
| Too few intended buyers are arriving | Targeting, distribution, partnerships, visibility |
| Buyers cannot recognize whether the offer fits | Positioning, audience definition, use-case clarity |
| Buyers understand the product but not its material value | Offer design, value architecture, messaging |
| Buyers cannot judge whether the claims are adequately supported | Evidence maturity, claim discipline, evidence translation |
| Buyers cannot assess adoption requirements | Implementation model, onboarding, integration, operational communication |
| Buyers cannot progress the decision internally | Sales enablement, stakeholder materials, procurement support |
| The answer differs across internal teams | Ownership, decision alignment, shared commercial guidance |
| The company does not yet know the answer | Product, evidence, commercial, or operational development |
This map is not a substitute for investigation. Several constraints may coexist, and a stalled opportunity cannot always be assigned to one cause. Its purpose is to prevent a specific error: repeating the visibility intervention simply because the desired commercial outcome did not follow it.
More visibility may still be appropriate. But that conclusion should follow an examination of what happened after qualified buyers arrived—not replace it.
A practical post-visibility review
A useful review does not need to become a complete funnel audit. It needs to identify where the interpretation changed.
Start with six questions:
- Did the increase in visibility include the intended organizational buyers?
- What was the first meaningful stage that did not improve?
- What decision did buyers appear unable to complete there?
- Which questions, hesitations, or requests repeatedly preceded the stop?
- Is the answer available and consistent inside the company?
- Which intervention would make that specific decision easier?
The answers may show that the company still has an awareness problem. They may show that the offer is difficult to evaluate. Or they may reveal that buyers have reached a question the business itself has not yet resolved.
Each conclusion leads somewhere different.
What the visibility push has actually given you
Before relevant visibility, limited commercial movement may still be explained by limited exposure.
After more appropriate buyers arrive and movement remains weak, continuing to describe the problem primarily as insufficient awareness becomes harder to justify.
The visibility push has not diagnosed the business. It has produced a more informative set of buyer behaviours.
Those behaviours can show where recognition fails to become evaluation, where evaluation fails to become organizational progress, and where the company may not yet have the answer required for either.
Before commissioning another campaign, identify the first decision qualified buyers still cannot complete. Then determine whether the answer needs to be made accessible, stabilized across the business, or developed in the first place.
If relevant buyers are finding your health product but not moving, Sense-Maker Hub can help you identify where product value, evidence and buyer needs have become disconnected—and build the positioning, content strategy or research-led content needed to close the right gap.
